280P Efficacy of avelumab + axitinib (A + Ax) vs sunitinib (S) by number of IMDC risk factors in patients (pts) with advanced renal cell carcinoma (aRCC): Subgroup analyses from the final analysis of the phase III JAVELIN renal 101 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Urology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/j.annonc.2024.10.300